573 related articles for article (PubMed ID: 22471664)
21. Angiogenesis and hypertension: the dual role of anti-hypertensive and anti-angiogenic therapies.
Ferroni P; Della-Morte D; Palmirotta R; Rundek T; Guadagni F; Roselli M
Curr Vasc Pharmacol; 2012 Jul; 10(4):479-93. PubMed ID: 22272903
[TBL] [Abstract][Full Text] [Related]
22. Resistance to antiangiogenic therapies.
Bartolotti M; Franceschi E; Poggi R; Tosoni A; Di Battista M; Brandes AA
Future Oncol; 2014 Jun; 10(8):1417-25. PubMed ID: 25052752
[TBL] [Abstract][Full Text] [Related]
23. VEGF targeted therapy in acute myeloid leukemia.
Rodriguez-Ariza A; Lopez-Pedrera C; Aranda E; Barbarroja N
Crit Rev Oncol Hematol; 2011 Nov; 80(2):241-56. PubMed ID: 21035354
[TBL] [Abstract][Full Text] [Related]
24. Selective VEGFR inhibitors for anticancer therapeutics in clinical use and clinical trials.
Zhang C; Tan C; Ding H; Xin T; Jiang Y
Curr Pharm Des; 2012; 18(20):2921-35. PubMed ID: 22571661
[TBL] [Abstract][Full Text] [Related]
25. Antiangiogenic therapy: targeting vascular endothelial growth factor and its receptors.
Tandle A; Libutti SK
Clin Adv Hematol Oncol; 2003 Jan; 1(1):41-8. PubMed ID: 16227959
[TBL] [Abstract][Full Text] [Related]
26. Role of VEGF/VEGFR in the pathogenesis of leukemias and as treatment targets (Review).
Song G; Li Y; Jiang G
Oncol Rep; 2012 Dec; 28(6):1935-44. PubMed ID: 22993103
[TBL] [Abstract][Full Text] [Related]
27. Vascular endothelial growth factor (VEGF), VEGF receptors and their inhibitors for antiangiogenic tumor therapy.
Takahashi S
Biol Pharm Bull; 2011; 34(12):1785-8. PubMed ID: 22130231
[TBL] [Abstract][Full Text] [Related]
28. Anti-FGF2 approaches as a strategy to compensate resistance to anti-VEGF therapy: long-pentraxin 3 as a novel antiangiogenic FGF2-antagonist.
Alessi P; Leali D; Camozzi M; Cantelmo A; Albini A; Presta M
Eur Cytokine Netw; 2009 Dec; 20(4):225-34. PubMed ID: 20167562
[TBL] [Abstract][Full Text] [Related]
29. VEGF in nuclear medicine: Clinical application in cancer and future perspectives (Review).
Taurone S; Galli F; Signore A; Agostinelli E; Dierckx RA; Minni A; Pucci M; Artico M
Int J Oncol; 2016 Aug; 49(2):437-47. PubMed ID: 27277340
[TBL] [Abstract][Full Text] [Related]
30. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis.
Hicklin DJ; Ellis LM
J Clin Oncol; 2005 Feb; 23(5):1011-27. PubMed ID: 15585754
[TBL] [Abstract][Full Text] [Related]
31. Targeting VEGF/VEGFRs Pathway in the Antiangiogenic Treatment of Human Cancers by Traditional Chinese Medicine.
Zhang C; Wang N; Tan HY; Guo W; Li S; Feng Y
Integr Cancer Ther; 2018 Sep; 17(3):582-601. PubMed ID: 29807443
[TBL] [Abstract][Full Text] [Related]
32. Pathways mediating resistance to vascular endothelial growth factor-targeted therapy.
Ellis LM; Hicklin DJ
Clin Cancer Res; 2008 Oct; 14(20):6371-5. PubMed ID: 18927275
[TBL] [Abstract][Full Text] [Related]
33. Thymic epithelial tumors express vascular endothelial growth factors and their receptors as potential targets of antiangiogenic therapy: a tissue micro array-based multicenter study.
Lattanzio R; La Sorda R; Facciolo F; Sioletic S; Lauriola L; Martucci R; Gallo E; Palmieri G; Evoli A; Alessandrini G; Ruco L; Rendina EA; Truini M; Chiarle R; Barreca A; Pich A; Ascani S; Remotti D; Tunesi G; Granone P; Ratto GB; Puma F; Pescarmona E; Piantelli M; Marino M; ; Carlini S; Cerasoli V; Corzani F; Melis E; Filippetti M; Canalini P; Palestro G; Lalle M; Ruffini E; Ceribelli A; Rinaldi M
Lung Cancer; 2014 Aug; 85(2):191-6. PubMed ID: 24908332
[TBL] [Abstract][Full Text] [Related]
34. Challenges facing antiangiogenesis therapy: The significant role of hypoxia-inducible factor and MET in development of resistance to anti-vascular endothelial growth factor-targeted therapies.
Mahdi A; Darvishi B; Majidzadeh-A K; Salehi M; Farahmand L
J Cell Physiol; 2019 May; 234(5):5655-5663. PubMed ID: 30515806
[TBL] [Abstract][Full Text] [Related]
35. Anti-Angiogenics: Their Value in Colorectal Cancer Therapy.
Seeber A; Gunsilius E; Gastl G; Pircher A
Oncol Res Treat; 2018; 41(4):188-193. PubMed ID: 29562227
[TBL] [Abstract][Full Text] [Related]
36. [Inhibition of the VEGF receptor system with tyrosine kinase inhibitors. Angiogenesis inhibition in oncology].
Mross K
Pharm Unserer Zeit; 2008; 37(5):404-15. PubMed ID: 18729270
[No Abstract] [Full Text] [Related]
37. Targeting tumor angiogenesis.
Gaur P; Bose D; Samuel S; Ellis LM
Semin Oncol; 2009 Apr; 36(2 Suppl 1):S12-9. PubMed ID: 19393831
[TBL] [Abstract][Full Text] [Related]
38. Exploring the Immunological Mechanisms Underlying the Anti-vascular Endothelial Growth Factor Activity in Tumors.
de Aguiar RB; de Moraes JZ
Front Immunol; 2019; 10():1023. PubMed ID: 31156623
[TBL] [Abstract][Full Text] [Related]
39. Tumor angiogenesis and anti-angiogenic therapies.
Shahneh FZ; Baradaran B; Zamani F; Aghebati-Maleki L
Hum Antibodies; 2013; 22(1-2):15-9. PubMed ID: 24284305
[TBL] [Abstract][Full Text] [Related]
40. Novel small-molecule inhibitors of the vascular endothelial growth factor receptor.
Adjei AA
Clin Lung Cancer; 2007 Feb; 8 Suppl 2():S74-8. PubMed ID: 17382028
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]